Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSZQAK)

• Drug Name: Amphetamine Drug Info
• Synonyms: Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Approved	[1]

• Cross-matching ID:
  PubChem CID: 3007
  ChEBI ID: CHEBI:2679
  CAS Number: CAS 300-62-9
  TTD Drug ID: DMSZQAK
  VARIDT Drug ID: DR00084
  INTEDE Drug ID: DR0106
  ACDINA Drug ID: D00036

Molecule-Related Drug Atlas

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[11]
Progesterone	DMUY35B	Premature labour	JB00	Approved	[12]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[13]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[14]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[15]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[16]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[17]
Dopamine	DMPGUCF	Parkinson disease	8A00.0	Approved	[18]
Nicotine	DMWX5CO	Nicotine dependence	6C4A.2	Approved	[19]
Propranolol	DM79NTF	Migraine	8A80	Approved	[20]

Drug(s) Transported By Organic cation transporter 3 (SLC22A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Migraine	8A80	Approved	[21]
Ergotidine	DM78IME	Respiratory allergy	4A80	Approved	[22]
Metformin	DM89QE1	Type-2 diabetes	5A11	Approved	[23]
Clonidine	DM6RZ9Q	Hypertension	BA00-BA04	Approved	[21]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[24]
Epinephrine	DM3KJBC	Allergy	4A80-4A85	Approved	[22]
Norepinephrine	DMOUC09	Sepsis	1G40-1G41	Approved	[22]
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[25]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[26]
Etilefrine	DM67PWD	Cardiovascular disease	BA00-BE2Z	Withdrawn from market	[27]

Drug(s) Transported By Organic cation/carnitine transporter 2 (SLC22A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Hypertension	BA00-BA04	Approved	[28]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[29]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[24]
Levacecarnine HCL	DMJBOCR	Cognitive impairment	6D71	Approved	[30]
Potassium chloride	DMMTAJC	Hypokalemia	5C77	Approved	[31]
Tiotropium	DMFDC0Q	Chronic obstructive pulmonary disease	CA22	Approved	[32]
Ipratropium	DMFQ320	Obstructive lung disease	CA22.Z	Approved	[32]
Mepyramine	DMB4SFH	Allergy	4A80-4A85	Approved	[33]
Acetylcarnitine	DM4UE3K	Migraine	8A80	Phase 4	[34]
Acetyl-L-carnitine	DM74HGJ	Discovery agent	N.A.	Investigative	[29]

Drug(s) Transported By Sodium-dependent noradrenaline transporter (SLC6A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Norepinephrine	DMOUC09	Sepsis	1G40-1G41	Approved	[35]

Drug(s) Transported By Sodium-dependent dopamine transporter (SLC6A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Parkinson disease	8A00.0	Approved	[36]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[37]
Bretylium	DM1FX74	Ventricular fibrillation	BC71.1	Approved	[38]
Benztropine	DMGZOVN	Parkinson disease	8A00.0	Approved	[39]

Drug(s) Targeting Trace amine-associated receptor-1 (TAAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lisdexamfetamine	DM6W8V5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[40]
Dextroamphetamine	DMMIHVP	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
Hydroxyamphetamine Hydrobromide	DMQSGM0	Horner syndrome	8D8A.1	Approved	[41]
SEP-363856	DMG2QP4	Schizophrenia	6A20	Phase 3	[42]
NT0202	DMCMIJ1	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[2]
SPD-465	DM7NV1I	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[2]
RG-7351	DMFGR98	Major depressive disorder	6A70.3	Phase 1	[43]
Tyramine	DM4UXT1	Discovery agent	N.A.	Investigative	[44]
EPPTB	DMK3VID	Discovery agent	N.A.	Investigative	[45]
R(-)amphetamine	DM72ES1	Discovery agent	N.A.	Investigative	[46]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Trace amine-associated receptor-1 (TAAR1)	TTIU98M	TAAR1_HUMAN	Modulator	[2] , [3] , [4] , [5] , [1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium-dependent dopamine transporter (SLC6A3)	DT3BA8L	SC6A3_HUMAN	Substrate	[6]
Sodium-dependent noradrenaline transporter (SLC6A2)	DT9JBVI	SC6A2_HUMAN	Substrate	[6]
Organic cation/carnitine transporter 2 (SLC22A5)	DT3HUVD	S22A5_HUMAN	Substrate	[7]
Organic cation transporter 3 (SLC22A3)	DT6201N	S22A3_HUMAN	Substrate	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Tyramine oxidase (tynA)	DEB3TNR	AMO_ECOLI	Substrate	[10]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
• [3] Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. J Neurochem. 2003 Jul;86(2):413-21.
• [4] Involvement of the alpha(1D)-adrenergic receptor in methamphetamine-induced hyperthermia and neurotoxicity in rats. Neurotox Res. 2013 Aug;24(2):130-8.
• [5] Methamphetamine increases the hippocampal alpha(2A)-adrenergic receptor and Galpha(o) in mice. Neurosci Lett. 2002 Dec 16;334(3):145-8.
• [6] Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
• [7] Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
• [8] Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
• [9] Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
• [10] Mechanistic elucidation of amphetamine metabolism by tyramine oxidase from human gut microbiota using molecular dynamics simulations. J Cell Biochem. 2019 Jan 30.
• [11] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [12] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [13] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [14] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [15] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [16] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [17] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [18] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [19] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [20] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [21] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [22] Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
• [23] Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
• [24] Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
• [25] Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31.
• [26] Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51.
• [27] Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
• [28] Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
• [29] Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
• [30] Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
• [31] Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
• [32] Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
• [33] Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
• [34] Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
• [35] Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51.
• [36] Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
• [37] Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl). 2017 Mar;234(6):1017-1028.
• [38] Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species? J Biol Chem. 1999 Feb 19;274(8):4876-82.
• [39] Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist. J Pharmacol Exp Ther. 2014 Jan;348(1):106-15.
• [40] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [41] Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37.
• [42] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [43] Clinical pipeline report, company report or official report of Roche.
• [44] Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS One. 2011;6(10):e27073.
• [45] The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6.
• [46] The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39.